1. One of These is Not Like the Other: Pathology Reports in Advanced NSCLC

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Rationale for Testing Newly Diagnosed Patients

4. Who Should Be Tested?

5. Where Is the Best Sample Site?

6. CAP/IASLC/AMP Currently Recommended Tests

7. What Determines a Positive Test Result?

8. CAP/IASLC/AMP IHC Testing Recommendations

9. Other Recommended Tests

10. Sampling Techniques

11. Testing Techniques

12. Best Practices for Timing

13. Best Practices for Reports

14. Rationale for Testing Upon Progression in EGFR Mutation-Positive Patients

15. Plasma, Tissue, and Urine Testing for T790M-Positive Patients

16. Cross-Comparison Plasma Testing

17. Best Practices With Liquid Biopsy

18. Osimertinib as First- and Second-Line Therapy

19. Concluding Remarks

20. Abbreviations

21. Abbreviations (cont)